References
- Dawson R, Buchwald U, Johnson K, et al. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Exp Rev Vaccines. 2022;21(6): doi:https://doi.org/10.1080/14760584.2022.2047023
- Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent Polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50.
- Andrews N, Waight P, George R, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808. Epub 2012 Sep 18
- Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020 Oct;17(10):e1003326. PubMed PMID: 33095759; eng
- Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non- vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451. PubMed PMID: 29395999; eng
- JCVI. Minute of the meeting on 07 October 2015.
- van Hoek AJ, Miller E. Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PloS One. 2016;11(2):e0149540. PubMed PMID: 26914907; PubMed Central PMCID: PMCPmc4767406. eng
- Goldblatt D, Miller E. Pneumococcal pneumonia. Thorax. 2020;75(1):6–7.
- Theilacker C, Fletcher M, Jodar L, et al. PCV13 vaccination of adults against pneumococcal disease: what we have learned from the community-acquired pneumonia immunization trial in adults (CAP-iTA). Microorganisms. 2022;10:127.